-tested the collection of standardized tobacco use variables. This study evaluated the capture of tobacco use data and examined smoking prevalence among cancer patients. METH-ODS: Participating registries collected data about the use of tobacco-cigarettes, other smoked tobacco, and smokeless tobacco-for cases diagnosed during 2011-2013. The percentage of cases with known tobacco variable values was calculated, and the prevalence of tobacco use was analyzed by the primary cancer site and state. RESULTS: Among 1,646,505 incident cancer cases, 51% had known cigarette use data: 18% were current users, 31% were former users, and 51% reported never using. The percentage of cases with a known status for both other smoked tobacco and smokeless tobacco was 43%, with 97% and 98% coded as never users, respectively. The percent known for cigarette use ranged from 27% to 81% by state and improved from 47% in 2011 to 59% in 2013 for all 10 states combined. The percent known for cigarette use and the prevalence of ever smoking cigarettes were highest for laryngeal cancer and tracheal, lung, and bronchus cancer. CONCLUSIONS: Cancer registrars ascertained cigarette use for slightly more than half of all new cancer cases, but other tobacco-related fields were less complete. Studies to evaluate the validity of specific tobacco-related variables and the ability of cancer registries to capture this information from the medical record are needed to gauge the usefulness of collecting these variables through cancer surveillance systems. Cancer 2018;124:2381-9.
INTRODUCTION
Tobacco use in the United States accounts for an estimated 167,805 cancer deaths each year. 1 Tobacco use at cancer diagnosis and during cancer care is associated with a worse disease prognosis. [2] [3] [4] [5] [6] US statistics on tobacco use are generated through surveys of the general population, such as the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS), and US cancer statistics are obtained from cancer patient medical records through cancer registries funded by the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC) or the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. 7 Surveys that ask about tobacco use (eg, BRFSS) assess responses from patients with and without self-reported cancer diagnoses but do not link tobacco use with confirmed cancer diagnosis information from the medical record.
Using cancer registries to collect tobacco use data has the potential to generate more reliable data regarding tobacco use patterns for patients diagnosed with cancer. Tobacco use data at diagnosis may help health professionals to better understand how tobacco use affects a cancer prognosis, 8 and this in turn may inform patient counseling regarding risks associated with tobacco use as well as the management of survivorship care. In addition, tobacco use data collected in cancer registries could help health professionals to identify cancer patients for tobacco cessation interventions.
Many statewide individual central cancer registries collect tobacco use data, but these variables are not standardized among cancer registries. To improve the datacapture capabilities of cancer registries, in 2011, the CDC started an enhanced data collection project in comparative effectiveness research (CER), which was funded through the American Recovery and Reinvestment Act. 9 The CER project secured funding for 10 statewide central cancer registries to collect and report new, standardized data variables, including tobacco use, height, and weight at diagnosis. 9 The quality and content of the tobacco use data from the CER project have not previously been reported. The purpose of this study was to evaluate the data quality of tobacco use data collected during 2011-2013 by the 10 CER states to inform recommendations on how best to collect these data in NPCR registries.
MATERIALS AND METHODS
Data were analyzed from 10 state-based central cancer registries funded by CDC's NPCR program for the CER project, as detailed by Chen et al. 9 State registries included the registries for Alaska, California, Colorado, Florida, Idaho, Louisiana, North Carolina, New Hampshire, Rhode Island, and Texas. 9 The collection of tobacco use variables was required statewide for all patients diagnosed with cancers of any anatomic site during 2011-2013. NPCR data from the 10 CER states during 2011-2013 met US Cancer Statistics publication criteria and covered 27.3% of the US population. 9 The CER project was approved by the CDC institutional review board. Patient consent was not needed for this study because the submitted data were deidentified before they were received by the CDC.
Cases included all new diagnoses of cancer, including all behavior codes (benign, borderline, in situ, and malignant), and first and subsequent malignant neoplasms. The primary site was classified with site codes based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). 10 Further analysis was performed for tobacco-associated cancers, which are those cancers considered by the US surgeon general to be causally associated with tobacco use. 11 Tobacco-associated cancer cases 11, 12 included ICD-O-3 histology codes 8000 to 9049, 9056 to 9139, and 9141 to 9589. Sites included the lip, oral cavity, and pharynx (C000-C148); esophagus (C150-C159); stomach (C160-C169); colon and rectum (C180-C209 and C260); liver (C220); pancreas (C250-C259); larynx (C320-C329); trachea, lung, and bronchus (C339-C349); cervix (C530-C539); kidney and renal pelvis (C649-C659); urinary bladder (C670-C679); and acute myeloid leukemia (9840, 9861, 9865-9867, 9869, 9871-9874, 9895-9898, 9910-9911, and 9920). 10, 13 There were 4 tobacco use variables included in the CER data set and this analysis: 1) cigarette smoking, 2) other smoked tobacco (eg, pipes, cigars, and kreteks), 3) smokeless tobacco, and 4) tobacco use not otherwise specified (NOS). The use status for each tobacco question was coded as 1) never user, 2) current user, 3) former user who had quit within 1 year from the diagnosis, 4) former user who had quit more than 1 year before the diagnosis, 5) former user with an unknown time since quitting, or 6) unknown. These 4 tobacco use variables were developed specifically for the CER project by a multidisciplinary study team that included expertise in oncology, registry operations, cancer surveillance, and epidemiology and included physicians, researchers, and other public health professionals at the CDC and at participating states. The tobacco use variables were designed to capture data likely to be available for abstraction from medical records. The study team aimed to specify the type of tobacco used, to achieve mutually exclusive coding options for the type of tobacco use and status, and to create variables similar to historical tobacco use variables already being collected by some states. The study team completed a literature review of previous data collection and epidemiological studies involving tobacco use variables to help inform the design of the data collection instrument. Once draft data collection fields were developed, the study team shared the design with the registry teams collecting the data to ensure that content was consistent and understood. Each state used the same single-field and interfiled edits and data submission record layout before data submission to ensure data quality and consistency. 9 Cancer registry data were abstracted from information documented in the medical records. The sources of these data included nursing assessment notes, flow charts, vital stats, and other available sources from the patient's hospital or physician office medical record.
14 Data from the CER project did not include where tobacco use information was found within the medical chart. The tobacco use status was defined by the use status at the date of diagnosis, as abstracted from medical records. The percent known was calculated by the division of the number of cases coded with known values (with those coded as unknown being excluded) by the total number of cases, as previously done. 15 All analyses were conducted with SEER*Stat version 8.3.2 (https://seer.cancer.gov/seerstat/).
RESULTS
From 2011 to 2013, 1,646,505 new diagnoses of cancer were reported to the 10 CER registries. The majority of cases (50.5%) represented individuals aged 60 to 79 years, and the median age was 66 years ( Table 1 ). The most common cancer diagnoses were digestive system cancer Among all tobacco use variables, the percent known was higher in females than males, was higher in blacks than all other races, and was higher in non-Hispanics than Hispanics. The percent known for cigarette use was highest for cases diagnosed at the ages of 40 to 79 years and was lowest for those aged 80 years. For all tobacco use variables, the percent known was highest for cases reported from a hospital or from a radiation or oncology center, which represented 88.8% and 1.9% of all cases, respectively.
For all 4 tobacco use variables, the percent known improved from 2011 to 2013 during the study interval (Fig. 1) . The percent known varied by state and ranged from 26.7% to 81.3% for the cigarette use variable (Fig. 2) .
Cigarette smoking was the most common form of tobacco use reported: 48.9% of cases ever smoked cigarettes, 2.8% ever smoked other tobacco products, and 1.8% ever used smokeless tobacco products (Table 2) . Current cigarette use was reported by 17.6% of cases, and former use was reported by 31.3%, with most of those users quitting more than 1 year before their diagnosis (Table 2) .
Cigarette use had a higher percent known among cases diagnosed with a tobacco-associated cancer (55.3%) in comparison with cases diagnosed with cancers not associated with tobacco use (49.0%; Table 3 ). The prevalence of ever smoking cigarettes was also higher among cases diagnosed with a tobacco-associated cancer (63.2%) than other cases (39.0%; Table 3 ). The percent known for cigarette use and the prevalence of ever smoking cigarettes were highest among cases diagnosed with laryngeal cancer or tracheal, lung, or bronchus cancer (Table 3) .
DISCUSSION
This is the largest study to assess the capture of tobacco use by cancer registry record abstraction to date. Information about cigarette use was ascertained for slightly more than half of all new cancer cases in our study, but other tobacco use variables had lower percentages known. The percent known improved steadily between 2011 and 2013 for each tobacco use variable, but it showed wide variation by state. The percentage of current and former use of tobacco products other than cigarettes was <3% in each case. Tobacco-associated cancers had both a higher cigarette use percent known and higher recorded percentages for current and former cigarette users. The percent known for tobacco use variables collected by cancer registries is not well described in the literature. A recent study by Sharp et al 6 using the National Cancer Registry Ireland reported a known smoking status for 77% of 10,794 rectal cancer cases. Using a variable vocabulary different from that of our study, the Massachusetts Cancer Registry, as part of a CDC-funded project from 2005 to 2009, reported 89.6% as the percent known for tobacco use variables among 5348 breast and colorectal cancer cases. 16 That study was limited to colorectal and breast cancers because they are more likely to be diagnosed and treated in a hospital setting. For the cigarette use variable, our study found 56.5% known for colorectal cancer and 56.0% known for breast cancer; these figures increased to 58.1% and 56.4%, respectively, when they were limited to cases found in hospital settings only. The percent known for cigarette use in our study may be higher than that for other tobacco use variables because cigarette use may be more often recorded in the medical record or may be easier for registrars to locate in the record. It is possible that the increase in the percent known from 2011 to 2013 reflects increased tobacco use reporting in the record or increased registrar familiarity with these registry variables.
The percent known for tobacco use variables in our study varied with several factors, including sex, age, race, ethnicity, state, and reporting source. These factors may have influenced a health care provider's likelihood to ask and record tobacco use, a patient's likelihood to report it, and the registrars' awareness of tracking and recording a Cases in this column served as the denominator for calculating the row percentages of ever, current, former, and never cigarette users. b The percent known was calculated by the division of the total known cases by the total cases. c Ever users represent the sum of the current and former user columns.
Cancer Registries Capturing Tobacco Use/Siegel et al
Cancer
June 1, 2018 these variables. The wide variation in the percent known between states (26.7%-81.3% for the cigarette use variable) may reflect whether tobacco variables were already being collected before the CER study; differences in the availability, use, and comprehensiveness of electronic health record (EHR) systems; or differences in variable acceptability. In addition, variable acceptability may be dependent on the emphasis placed by local and state registry leadership on recording tobacco use. Differences in coding practices by state, such as coding "never used" instead of "unknown," or differences in the use of the tobacco use NOS code may explain further variation.
The percent known for cigarette use was higher for tobacco-associated cancers than other cancers and was highest for laryngeal cancer and tracheal, lung, and bronchus cancer. The higher percent known among tobaccoassociated cancers may reflect differences in clinical practice because registries and registrars were not instructed to code tobacco-associated cancers differently than other cancers. This difference suggests that health care providers may document tobacco use history more frequently when they are diagnosing tobacco-associated cancers.
The percentages of never, current, and former tobacco users in our study were similar to national results from past studies. [17] [18] [19] [20] [21] In 2015, 15.1% of US adults reported being current cigarette smokers in the NHIS, whereas 17.6% of adults in this study were current cigarette smokers. 17 According to 2014 BRFSS data, the cigarette smoking prevalence ranged by state from 9.7% in Utah to 26.7% in West Virginia. 18 However, in addition to all cases having been diagnosed with cancer, the NPCR population is different from the NHIS and BRFSS populations in other respects, such as the age distribution and the number of states represented. 22 A telephone interview study of 20,891 patients with breast cancer during 1988-2008 reported a cigarette smoking prevalence of 20%, 19 whereas in our study, 17.6% of breast cancer cases were current cigarette users. Past literature has reported cigarette use prevalence above the national average in patients with tobacco-associated cancers such as lung and laryngeal cancers. 20, 21 A 2012 study by Park et al 20 reported that 38.7% of patients with lung cancer had reported current smoking at diagnosis, and 90.2% were ever smokers; these figures are comparable to those for current (36.4%) and ever smokers (85.1%) among cases with tracheal, lung, or bronchus cancer in our study. The 2012 National Substance and Drug Use and Health survey data reported that 3.5% of US adults used smokeless tobacco in the past month; this is higher than the figure of 0.9% for smokeless tobacco current users reported in our study. 23 Although survey-based tobacco use surveillance relies on the respondent's recall of his or her tobacco use, studies show that the smoking status has been reliably selfreported. 24 Similarly, reviews of electronic medical records have indicated that current tobacco use is reliably recorded, although past tobacco use may be underrecorded. 25, 26 Although the response rate of tobacco use questions in the BRFSS ranges from 25.1% to 60.1% and is dependent on the US state, 18 the rate of documentation of tobacco use in electronic medical records was 64.4% in a Canadian study of EHRs looking at 249,223 patients. 27 Because of the Meaningful Use Initiative in the United States, which encourages hospitals and clinics to record the smoking history in EHRs for at least 80% of patient encounters, 28 the recording of tobacco use in EHRs may be improving. 29 The development of standards for how tobacco use is most accurately and easily recorded and subsequently accessed for clinical or research use in EHRs may improve the ease of data collection for registrars and improve the percent known for tobacco use variables.
Data with a high percent known and high data validity have the potential to be used to better understand the relation between tobacco use and cancer outcomes such as progression, recurrence, secondary cancers, and mortality. Known tobacco use among cancer patients can also inform cancer control programs and the recruitment of patients for tobacco use cessation interventions. 30 Past studies have used cancer registries to recruit patients for outreach for cancer survivors and for breast cancer screening. [31] [32] [33] Tobacco use data from cancer registries could enable health professionals to identify patients who use tobacco at diagnosis or to track patients' tobacco use after diagnosis. However, ideal methods for contacting this patient population and recording the most recent smoking status will need further evaluation. A study using local cancer registries to identify patients for smoking cessation interventions found that 71% of 577 individuals listed as current cigarette smokers in the registry at cancer diagnosis were identified as current cigarette smokers during a follow-up abstraction of EHR records 6 to 24 months after their diagnosis. 34 In addition, standardized tobacco use information at diagnosis could be incorporated into clinical trials that use a follow-up evaluation to assess the impact of smoking on the prognosis. 35 Because the smoking status at and after diagnosis significantly affects the prognosis, [2] [3] [4] there is the potential to incorporate the smoking status into clinical decisions regarding tobacco cessation interventions or the management of survivorship care. In contrast, a low percentage of people were recorded as using other tobacco products; this may lead to challenges in identifying patients for intervention efforts and in delivering public health interventions and thus limit the usefulness of other tobacco use variables.
The collection of the tobacco use status through cancer registries depends on the accuracy of the health care providers recording tobacco use, the ease of the registrars in finding this information in the record, and the acceptability among state registries in collecting these data. In addition, because cancer cases are sometimes not abstracted until close to 6 months after the diagnosis and are not reported to the state until as late as 2 years after the diagnosis (depending on the state), some registries may have limited usefulness for enrolling patients in immediate smoking cessation interventions. Furthermore, increasing the data collection burden on cancer registrars may increase registry operating costs, especially because modifications to software would be needed to standardize tobacco use data collection. 36 This study had several limitations. Although data from 10 central cancer registries were included in the CER study, the results may not be generalizable to other states. Second, despite registry quality standards and an overall high quality of data, 37 variables in the NPCR and associated registries may be subject to coding misclassification. The internal validity of tobacco use data and the degree of potential coding misclassification are not well documented in the literature and may vary by additional factors such as the reporting source, age, sex, and type of cancer diagnosis. The NPCR smoking variables did not assess the amount or duration of tobacco use (eg, packyears), which is a valuable tool and is used by other organizations, including the Centers for Medicare and Medicaid Services (as part of lung cancer screening eligibility criteria) and the American Joint Committee on Cancer. 38, 39 Pack-years were not included in the CER study because the level of detail needed to access this information accurately is not routinely and consistently available in the medical records from which abstractors collected the CER study data. In addition, it is known that EHRs underestimate pack-years or have missing pack-year data, 40, 41 and in the context of a survey, multiple questions are required for an accurate assessment. 42 Adding pack-years to CER tobacco use variables for registrar abstraction may require further data validation and standardization. 40 Finally, electronic cigarette (e-cigarette) use and nicotine gum use were not included in tobacco use variable data abstraction, although states were asked to note the use of these items in a text field for future reference. Although e-cigarette use has been increasing in prevalence, 43 the use of e-cigarettes presents a different toxicity profile than cigarette use 44 and may have further complicated the study's aim of collecting tobacco use data.
There may be several ways to improve the quality of tobacco use variables. First, because of the low percent known and low percentages of ever users reported for noncigarette tobacco use variables, cancer registries could consider focusing on cigarette smoking only. The Meaningful Use Initiative asked only about cigarette smoking instead of all forms of tobacco use to focus on 1 quality objective that maximizes the public health impact. 45 Focusing on cigarette use may lead to higher variable acceptability and reliability. Second, the quality of tobacco use data collected by cancer registries is dependent on the documentation in the medical record. The education of providers as well as policies that incentivize documenting tobacco use may improve tobacco use documentation. 46, 47 Third, standardization of tobacco use variables may be needed to improve variable quality and best address public health planning needs. 35 Finally, further data validation will be needed. The wide variation in results by state may suggest a need for a further evaluation of methods and quality registry reporting. Future studies could internally validate tobacco use variables by comparing registry data with a record review or patient interview gold standard.
In conclusion, tobacco use data collected through cancer registries could strengthen public health efforts in reducing the burden of tobacco-associated cancers. Continued partnership between the cancer registry community and initiatives such as the Meaningful Use Initiative that better define EHR variables will increase variable quality to the benefit of health care providers, patients, public health planners, and researchers. 
